A Phase 1 interventional study of PF-08049820 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 31st largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2024, is one of 13 in phase 1, and was the 48th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see:
The study medicine is developed for the treatment of moderate to severe atopic dermatitis, also known as eczema. People with this condition may have severe itching and rashes on the skin.
The study is seeking participants who:
Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).
For group or cohort 3 only:
The study has three parts: Part A, Part B and Part C.
Part A consists of 3 groups (also known as "cohorts"). In Cohorts 1 and 2, there may be up to four dosing periods. During each dosing period, participants will take a single dose of the study medicine or placebo as liquid by mouth with or without food at the study clinic. A placebo does not have any medicine in it but looks just like the medicine being studied. The participants will stay at the study clinic for about 8 days and then can go home. During this time, the study team will observe the participants and take some urine and blood samples to test the level of the study medicine. The participants will return to the study clinic up to three more times to complete up to four dosing periods separated by at least 2 weeks. The participants will take increasing amounts of study medicine during each dosing period. After completion of the final dosing period, the participants will receive a follow-up telephone call about a month later. Cohort 3 consists of one dosing period and will enroll participants who have 4 biological Japanese grandparents who were born in Japan. Participants will be checked as described above and will receive a follow-up telephone call about one month after the last dose of study medicine or placebo.
Part B has 4 cohorts (Cohorts 4 to 7), each consisting of one dosing period. In all cohorts, participants will take multiple doses of the study medicine or placebo as tablets by mouth at the study clinic. Part C has two cohorts (Cohort 8 and 9), each consisting of one dosing period. In both cohorts, participants will take a single dose of the study medicine or placebo as tablets by mouth at the study clinic. Participants will be checked as described above and will receive a follow-up telephone call about one month after the last dose of study medicine or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.). Japanese participants only: a total body weight >45 kg is acceptable.
Cohort 3 only:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.
Drug: PF-08049820 · Drug: Placebo
Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.
Drug: PF-08049820 · Drug: Placebo
One dosing period with a single dose of PF-08049820 or placebo in healthy adult Japanese participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with a single dose of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
One dosing period with a single dose of PF-08049820 or placebo in healthy adult participants.
Drug: PF-08049820 · Drug: Placebo
Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Parts B and C (Cohorts 4 to 9).
Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Parts B and C (Cohorts 4 to 9).
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B
Number of Participants With Serious Adverse Events (SAEs)
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Part A (Cohorts 1 to 3) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 8 of last dosing period for Parts A and C
Area under the curve from time zero to end of dosing interval (AUCtau)
Part B (Cohorts 4 to 7)
Time frame: Baseline up to Day 13 for Part B
Maximum observed plasma concentration (Cmax)
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B
Time to reach maximum observed plasma concentration (Tmax)
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B
Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B
Plasma decay half-life (t1/2) if data permit
Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)
Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B
Amount of unchanged drug recovered in urine during dosing interval (Aetau)
Part B (Cohorts 4 to 7)
Time frame: Baseline up to Day 10 for Part B
Percent of dose recovered in urine as unchanged drug over dosing interval (Aetau%)
Part B (Cohorts 4 to 7)
Time frame: Baseline up to Day 10 for Part B
Renal clearance (CLr)
Part B (Cohorts 4 to 7)
Time frame: Baseline up to Day 10 for Part B
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2024 to primary completion in Feb 2026, 14 months.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-08049820